Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Targeting melanoma cells with a drug-infused graphene matrix

Dr Livia Sima of the Institute of Biochemistry of the Romanian Academy and Dr Emanuel Axente of the National Institute for Laser, Plasma, and Radiation Physics in Romania are developing novel platforms for screening of therapeutic drug combinations for patients with metastatic melanoma.

A Cure In Sight, in partnership with the UCSF Ocular Oncology Center and NORD, Launches Landmark Ocular Melanoma Natural History Study

Cleveland, OH, September 28, 2020—A Cure in Sight and the National Organization for Rare Disorders have launched an innovative study to research ocular melanoma, a disease that can cause blindness, loss of the eye and even death from spread to other organs.

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

Alexander M. M. Eggermont, MD, PhD, professor of oncology, University of Paris-Sud, professor of oncological surgery, chair, International Research Network on Cancer, Erasmus University of Rotterdam, Joseph Maisin Honorary Chair of Oncological Surgery, Louvain Catholic University, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ?evaluating adjuvant pembrolizumab (Keytruda) versus placebo, in advanced melanoma.

Researchers Keep Cancer Cells Out by Blocking the Gate to the Nucleus

The nucleus of a cell is centrally important to an organism. It stores and organizes genetic information, while separating and protecting this very important information from the host of other cellular components.